Insider Trading May 15, 2026 08:47 PM

Director Sale and Recent Earnings Surge at Trio-Tech International

Analysis of insider transactions alongside significant revenue growth and capital raising activities.

By Derek Hwang TRT

Trio-Tech International (NASDAQ:TRT) recently disclosed that a director executed multiple sales of common stock in early March 2026. Despite this activity, the company has reported substantial financial milestones, including a 124% revenue increase for its third quarter and the successful completion of a direct offering to fund AI expansion. These developments paint a complex picture regarding internal confidence and market valuation.

Director Sale and Recent Earnings Surge at Trio-Tech International
TRT

Key Points

  • The company's Q3 revenue growth was substantial, achieving a 124% increase, reaching $16.5 million from $7.4 million in the prior year.
  • Growth was particularly strong within the semiconductor back-end solutions segment, which saw a notable 141% jump in revenue.
  • Trio-Tech successfully raised capital by completing a registered direct offering, selling over 1 million shares and collecting approximately $10 million to support AI expansion.

Analysis of insider activity at Trio-Tech International (NASDAQ:TRT) reveals that Jason Adelman, a director with the company, sold a total of 22,000 shares of common stock. The cumulative value of these transactions reached $123,570. These sales were spread across several dates during early March 2026, and the corresponding share prices ranged between $5.5322 and $5.8164.

The divestiture occurred in multiple distinct blocks. Specifically, on March 5, 2026, Mr. Adelman disposed of 4,511 shares at a price point of $5.5475 per share. The subsequent day, March 6, 2026, saw the sale of an additional 7,489 shares, priced at $5.5322 per share. Further sales were recorded on March 10, 2026, involving a block of 5,000 shares sold at $5.8164 per share. Finally, the transactions concluded on March 16, 2026, when another set of 5,000 shares was sold at $5.6066 per share.


These reported sales were documented via a Form 4 filing with the Securities and Exchange Commission on May 15, 2026. Following these transactions, Mr. Adelman maintains a direct holding of 50,000 shares of Trio-Tech International common stock.


The current market performance of TRT contrasts sharply with the prices at which these sales took place. The stock has experienced a dramatic surge since early March, currently trading at $20.05, a price point nearly four times higher than the average sale rates disclosed by Mr. Adelman. Furthermore, the company reported an impressive 710% return over the past year.

However, while recent financial metrics are strong, data from InvestingPro suggests that the stock may currently be overvalued relative to its established Fair Value estimate. Additionally, the platform highlights that TRT

Risks

  • The stock is flagged as potentially overvalued relative to its Fair Value estimate according to InvestingPro data.
  • Trio-Tech disclosed a cybersecurity incident at its Singapore subsidiary. Although initially considered non-material, it escalated to a material event due to unauthorized data disclosure and the company is addressing the impact of this ransomware attack.
  • The stock generally trades with high price volatility, as noted by InvestingPro Tips.

More from Insider Trading

KBR Director's Stock Purchase Amid Valuation and Earnings Data May 15, 2026 Insider Activity and Recent Financing Boost Confidence in Apogee Therapeutics May 15, 2026 Wheels Up CSO Sells Shares Amid Company Modernization and Financial Developments May 15, 2026 Insider Activity at Oruka Therapeutics Highlights Executive Stock Transactions Amid Clinical Progress May 15, 2026 Director Sales at Trio-Tech International Highlight Recent Insider Transactions and Company Developments May 15, 2026